RxDoctor Payments Data

Christina Hutchins, MD

Family Medicine · Johnson City, TNNPI 1245235423

Payments from drug & device makers

$8,153in general payments, 2019–2025

Across 547 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$962
  • Amgen$750
  • AstraZeneca$613
  • Lilly USA, LLC$612
  • Novo Nordisk$493
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$8,117100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,153 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$140,276
Medicare patients
202
Services billed
5,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$131,458
EliquisApixaban151$100,754
JardianceEmpagliflozin53$51,949
XareltoRivaroxaban53$49,131
FarxigaDapagliflozin Propanediol59$43,196
TrulicityDulaglutide32$38,277
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$38,187
MounjaroTirzepatide33$33,180
JanuviaSitagliptin Phosphate45$27,990
Repatha SureclickEvolocumab38$25,456
TradjentaLinagliptin39$22,183
LinzessLinaclotide26$21,432
Breo ElliptaFluticasone/Vilanterol29$15,242
TrintellixVortioxetine Hydrobromide29$13,503
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen370$10,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$493$131,458114 claims
PfizerEliquis$260$100,754151 claims
Boehringer IngelheimJardiance, Tradjenta$192$74,13292 claims
Lilly USA, LLCTrulicity, Mounjaro$612$71,45765 claims
AstraZenecaFarxiga, Brilinta, Symbicort$613$60,30996 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$962$59,70077 claims
Johnson & JohnsonXarelto$48$49,13153 claims
AbbVieLinzess, Synthroid, Combigan$1,323$29,36193 claims
MerckJanuvia$32$27,99045 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$307$13,50329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →